Sec Form 13G Filing - Samsara BioCapital L.P. filing for PALVELLA THERAPEUTICS INC. (PVLA) - 2024-12-20

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
SCHEDULE 13G 0001699737 XXXXXXXX LIVE Common Stock, $0.001 par value per share 12/13/2024 0001583648 Palvella Therapeutics, Inc. 697947109 125 Strafford Ave, Suite 360 Wayne PA 19087 Rule 13d-1(c) Samsara BioCapital, L.P. b DE 0.00 679486.00 0.00 679486.00 679486.00 6.1 PN Samsara BioCapital GP, LLC b DE 0.00 679486.00 0.00 679486.00 679486.00 6.1 OO Srinivas Akkaraju b X1 0.00 679486.00 0.00 679486.00 679486.00 6.1 IN Palvella Therapeutics, Inc. 125 Strafford Ave, Suite 360, , Wayne, PA, 19087. The names of the persons filing this report (collectively, the "Reporting Persons") are: Samsara BioCapital, L.P. ("Samsara LP") Samsara BioCapital GP, LLC ("Samsara GP") Srinivas Akkaraju ("Dr. Akkaraju") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. c/o Samsara BioCapital, LLC 628 Middlefield Road Palo Alto, CA 94301 Samsara LP Delaware Samsara GP Delaware Dr. Akkaraju United States Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Samsara LP directly holds 679,486 shares of Common Stock. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is a managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon 11,221,307 shares of Common Stock outstanding as of December 13, 2024, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 16, 2024. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Samsara BioCapital, L.P. /s/ Srinivas Akkaraju 12/20/2024 Samsara BioCapital GP, LLC /s/ Srinivas Akkaraju 12/20/2024 Srinivas Akkaraju /s/ Srinivas Akkaraju 12/20/2024